BioNTech SE

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -1.48%348.370.0%$6628.74m
BNTXBioNTech SE 3.61%340.210.0%$1132.49m
SNSSSunesis Pharmaceuticals, Inc. 3.71%10.910.7%$762.65m
NVAXNovavax, Inc. 3.48%185.5679.8%$671.59m
AMGNAmgen, Inc. -0.56%240.191.3%$496.45m
BIIBBiogen, Inc. 1.86%332.791.7%$439.25m
VRTXVertex Pharmaceuticals, Inc. -1.54%198.471.9%$408.33m
GILDGilead Sciences, Inc. 0.02%68.301.0%$401.36m
REGNRegeneron Pharmaceuticals, Inc. 0.41%576.992.7%$355.35m
ILMNIllumina, Inc. -0.35%494.023.5%$263.09m
NTLAIntellia Therapeutics, Inc. -2.52%138.282.3%$257.25m
CRSPCRISPR Therapeutics AG 1.89%123.310.6%$147.46m
EXASEXACT Sciences Corp. 1.24%109.1718.1%$125.11m
XBIOXenetic Biosciences, Inc. 20.40%4.900.0%$123.02m
SGENSeagen Inc. 0.16%153.645.8%$120.42m

Company Profile

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.